Adagene (ADAG) Other Accumulated Expenses (2019 - 2025)
Adagene (ADAG) posted quarterly Other Accumulated Expenses of $10.3 million for Q4 2025, down 21.54% year-over-year from $13.2 million in Q4 2024, and down 28.39% quarter-over-quarter from $14.4 million in Q2 2025.
Analysis
Adagene (ADAG) Other Accumulated Expenses (2019 - 2025) Analysis & Trends
Adagene (ADAG) has reported Other Accumulated Expenses for 7 consecutive years, with $10.3 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Other Accumulated Expenses fell 21.54% year-over-year to $10.3 million; the TTM figure through Dec 2025 stood at $10.3 million (down 21.54% YoY), while the FY2025 annual figure was $10.3 million, down 21.54% from the prior year.
- Other Accumulated Expenses fell to $10.3 million in Q4 2025 per ADAG's latest filing, from $14.4 million in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $19.3 million in Q4 2022 and bottomed at $143060.0 in Q4 2021.
- Historically, Other Accumulated Expenses has averaged $13.1 million across 5 years, with a median of $14.4 million in 2025.
- Annual changes were most pronounced in 2022 — Other Accumulated Expenses soared 13407.16% — and 2025, when it slipped 21.54%.
- Adagene's Other Accumulated Expenses stood at $143060.0 in 2021, then jumped by 13407.16% to $19.3 million in 2022, then dropped by 13.5% to $16.7 million in 2023, then slipped by 21.1% to $13.2 million in 2024, then slipped by 21.54% to $10.3 million in 2025.
- Business Quant data shows ADAG's Other Accumulated Expenses at $10.3 million in Q4 2025, $14.4 million in Q2 2025, and $13.2 million in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Adagene | 211.24 Mn | 211.24 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 10.35 Mn |
| Jun 30, 2025 | 14.45 Mn |
| Dec 31, 2024 | 13.19 Mn |
| Jun 30, 2024 | 17.33 Mn |
| Dec 31, 2023 | 16.71 Mn |
| Dec 31, 2022 | 19.32 Mn |
| Dec 31, 2021 | 143,060.00 |
| Dec 31, 2020 | 145,664.00 |
| Dec 31, 2019 | -15.80 Mn |